Poseida Therapeutics, Inc.
4250 Campus Point Court
Suite 700
San Diego
California
92121
United States
Website: http://poseida.com/
Email: info@poseida.com
89 articles with Poseida Therapeutics, Inc.
-
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
-
Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
-
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
-
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting
11/9/2021
Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced the upcoming presentation of preclinical data highlighting P-BCMA-ALLO1 for the treatment of relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for the treatment of multiple solid tumor indications at the Society for Immunotherapy of Cancer 2021 Annual Meeting (SITC).
-
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021
11/9/2021
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the third quarter ended September 30, 2021.
-
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences - Nov 03, 2021
11/3/2021
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Company will participate in the following upcoming virtual investor conferences:
-
Poseida Therapeutics Announces Leadership Appointments
10/13/2021
Poseida Therapeutics, Inc. today announced appointments to new roles on its executive leadership team.
-
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
10/12/2021
Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced that it has entered into a research collaboration and exclusive license agreement with Takeda Pharmaceutical Company Limited ("Takeda").
-
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
-
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting
10/1/2021
Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
-
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences in September 2021
9/7/2021
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Company will participate in the following upcoming virtual investor conferences.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
8/31/2021
Poseida Therapeutics, Inc. today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC).
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
8/30/2021
Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-BCMA-ALLO1, the Company's first fully allogeneic CAR-T product candidate for patients with relapsed/refractory multiple myeloma.
-
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021
8/12/2021
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced program updates and financial results for the second quarter ended June 30, 2021.
-
Poseida Therapeutics Appoints Cynthia Collins to Board of Directors
7/26/2021
Poseida Therapeutics, Inc. today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.
-
Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing
7/14/2021
Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, announced that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, has joined its Early Access Partnership Program.
-
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
6/2/2021
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that its Annual Meeting of Stockholders will be held virtually via live webcast on Wednesday, June 16, 2021 at 1:00pm PT.
-
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
5/11/2021
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced program updates and financial results for the first quarter ended March 31, 2021.
-
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting
5/11/2021
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting